Sarepta Therapeutics, Inc. (SRPT) - Technical Look

Mae Love
April 26, 2018

The stock decreased 2.82% or $2.2 during the last trading session, reaching $76.11. On Friday, March 2 the stock of Sarepta Therapeutics, Inc. SRPT outperformed by 138.35% the S&P500. Utah Retirement Sys reported 0.01% stake. The company has a market cap of $5,197.62, a PE ratio of -46.59 and a beta of 1.28.

The stock decreased 1.24% or $0.97 during the last trading session, reaching $77.34.

BTE's price to sales ratio for trailing twelve months is 1.41 and price to book ratio for most recent quarter is 0.62, whereas price to cash per share for the most recent quarter is N/A. The Toronto-Dominion Bank (NYSE:TD) has risen 15.54% since April 21, 2017 and is uptrending. It has outperformed by 53.81% the S&P500.

Big Money Sentiment decreased to 1.22 in 2017 Q4.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) closed up +0.16 points or 1.83% at $8.91 with 0.13 mln shares exchanging hands.

15 analysts on average are expecting Sarepta Therapeutics, Inc.to report earnings of $-0.3 per share for the current quarter. 70 grew stakes while 45 funds amassed stakes. Short-term as well long term investors always focus on the liquidity of the stocks so for that concern, liquidity measure in recent quarter results of the company was recorded 13.90 as current ratio and on the opponent side the debt to equity ratio was 0.55 and long-term debt to equity ratio also remained 0.54.

The company is expected to report earnings of $-0.32 a share for the next quarter. Principal Group Incorporated stated it has 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) are the two most active stocks in the Auto Parts industry based on today's trading volumes. Sphera Funds Mgmt reported 384,997 shs or 2.51% of all its holdings. Emerald Advisers Pa holds 886,979 shares.

Trump tweeted a unusual , racist term and Sarah Sanders has no explanation
Acosta returned to the topic later, asking Sanders if she considers the Trump administration "a champion of a free press". The Trump administration supports a free press - just not a rude one.

Nasdaq Open To Creating A Crypto Exchange, Says CEO
Securities and Exchange Commission) is right that those are securities and need to be regulated as such". It's just a matter of how long it will take for that space to mature.

United Nations expects over $4bn in pledges for Syria
About 70,000 people are in dire need of aid in Douma after one of the most intense military battles in Syria's seven-year war. Achim Steiner, head of the U.N.

Investors also need to beware of the Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Washington-based Fisher Asset Mngmt Limited Liability Co has invested 0% in Sarepta Therapeutics, Inc.

Granite Point Capital Mgmt L P reported 0.24% in Sarepta Therapeutics, Inc. UBS reaffirmed an "outperform" rating and set a $56.51 price target (down from $76.00) on shares of Sarepta Therapeutics in a research report on Wednesday, December 27th. State Of Wisconsin Inv Board owns 59,000 shares or 0.01% of their USA portfolio. Hudson Bay Cap Management Limited Partnership owns 170,400 shs. Peddock Advsr Limited Co owns 54 shares for 0% of their portfolio. Hanson Mcclain Inc stated it has 699 shares. Thrivent Financial For Lutherans holds 9,000 shares.

A total of 14 analysts rate Sarepta Therapeutics (NASDAQ:SRPT) as follows: 12 "Buy", 2 "Hold" and 0 "Sell". Therefore 86% are positive. (SRPT) has an Analysts' Mean Recommendation of 1.8, according to data compiled by Finviz. On Thursday, October 26 the stock has "Buy" rating by Needham. The Price Range 52 Weeks is one of the tools that investors use to determine the lowest and highest price at which a stock has traded in the previous 52 weeks. RBC Capital Markets maintained the stock with "Outperform" rating in Friday, October 28 report. On Monday, September 19 the stock rating was upgraded by PiperJaffray to "Overweight". On Wednesday, March 14 the company was maintained by JP Morgan. The stock of Sarepta Therapeutics, Inc. (NASDAQ:HAWK) on Thursday, October 12 with "Buy" rating. H.C. Wainwright has "Buy" rating and $1900 target. The stock of Sarepta Therapeutics, Inc.

SRPT has been the topic of several other research reports. During the same quarter in the prior year, the company posted ($0.71) earnings per share. Fred Alger Management Inc. now owns 1,581,525 shares of the biotechnology company's stock valued at $87,996,000 after purchasing an additional 149,712 shares during the period.

Among 5 analysts covering Calithera Biosciences (NASDAQ:CALA), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 50% are positive. Liberty Lilac Group had 19 analyst reports since August 3, 2015 according to SRatingsIntel. The formula is calculated by looking at companies that have a high earnings yield as well as a high return on invested capital. Stifel Nicolaus has "Hold" rating and $13 target. The rating was maintained by Barclays Capital on Friday, September 1 with "Equal-Weight". Piper Jaffray maintained the stock with "Buy" rating in Thursday, February 22 report. Janney Montgomery Scott started coverage on Sarepta Therapeutics in a research note on Wednesday, January 3rd. (NASDAQ:SRPT) on Monday, January 18 to "Neutral" rating. The firm earned "Buy" rating on Friday, September 11 by Pivotal Research. As per Friday, May 6, the company rating was downgraded by Goldman Sachs. Dynamic Solutions Ltd Com holds 0.54% or 94,083 shares in its portfolio. (NYSE:GMED) to report earnings on May, 2. They expect $1.16 EPS, up 16.00% or $0.16 from last year's $1 per share. MIK's profit will be $69.13M for 12.33 P/E if the $0.38 EPS becomes a reality. The biotechnology company reported ($0.37) EPS for the quarter, missing the Zacks' consensus estimate of ($0.32) by ($0.05).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER